Tirzepatide

替尔泊肽

Report date: 2026/05/25 20:02:40
NMEFirst In Class

Base Information

Drug NameTirzepatide
Drug Alias NameMounjaroZepbound穆峰达Mounjaro KwikPenZEPBOUND KwikPen +[7] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeLarge intestine neoplasmBinge-Eating Disorder +[47] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2022/05/13
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterThe Brigham and Women's HospitalUT Health San Antonio +[28] 
Inactive CompaniesHudson BiotechStanford UniversityBrightgene Bio-Medical Technology Co Ltd +[4] 
Active IndicationsPost-Acute COVID-19 SyndromeLarge intestine neoplasmBinge-Eating Disorder +[42] 
Inactive IndicationsEndocrine System DiseasesNutritional and Metabolic DiseasesKidney Failure, Chronic +[5] 

Other Information

ATC CodeA10BX16
Related LinksWikipediaDrugBankKEGG